Medicare proposes coverage limits for anti-anemia drugs

Medicare has proposed new restrictions on what it will cover for cancer patients prescribed anti-anemia drugs known as erythropoiesis-stimulating agents because of ties to death risks. Amgen makes Aranesp and Epogen and Johnson & Johnson makes Procrit for treating the problem, and they are expected to suffer the hardest hit if the Medicare proposal becomes final.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA